Establishment and characterization of a plasma cell leukaemia cell line dependent for growth on IL-6 and a bi-phenotypic subclone dependent upon both IL-3 and IL-6.
A human plasma cell leukaemia cell line (HSM-2) and a subclone (HSM-2.3) have been established from the bone marrow of a patient with bi-phenotypic leukaemia. Proliferation assays using a variety of cytokines demonstrated that HSM-2 proliferated in response to recombinant interleukin-6 (rIL-6), but did not respond to rIL-1, rIL-2, rIL-3, rIL-4, rIL-5, recombinant granulocyte-colony stimulating factor (rG-CSF), or recombinant granulocyte-macrophage-colony stimulating factor (rGM-CSF), and that HSM-2.3 responded to rIL-3 and rIL-6. HSM-2 expressed the CD38 (OKT10), PCA-1, cytoplasmic-IgM, and surface kappa light chain. HSM-2.3 expressed the CD14 (My4), CD33 (My9), CD38 (OKT10), CD19 (B4), CD24 (OKB2), CD10 (J5), PCA-1. HSM-2 and HSM-2.3 are useful tools for analysing the possible role of IL-3 and IL-6 in the oncogenesis of plasma cell leukaemia.
Kobayashi
M
M
Third Department of Internal Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
Miyagishima
T
T
Imamura
M
M
Maeda
S
S
Gotohda
Y
Y
Iwasaki
H
H
Sakurada
K
K
Miyazaki
T
T
D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000032:analysis; D000954:Antigens, Surface / Q000032:analysis; D001853:Bone Marrow / Q000473:pathology; D002455:Cell Division / Q000187:drug effects*; D002461:Cell Line, Transformed; D002999:Clone Cells; D006801:Humans; D016130:Immunophenotyping; D007377:Interleukin-3 / Q000494:pharmacology*; D015850:Interleukin-6 / Q000494:pharmacology*; D007952:Leukemia, Plasma Cell / Q000276:immunology / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D011994:Recombinant Proteins
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D007377:Interleukin-3; D015850:Interleukin-6; D011994:Recombinant Proteins